Kremers Urban Pharmaceuticals Inc. Settles Concerta® Patent Litigation

PRINCETON, N.J., Sept. 13, 2011 /PRNewswire/ -- Kremers Urban Pharmaceuticals Inc. is pleased to announce that it has reached a settlement dismissing all pending litigation arising from its Abbreviated New Drug Application (ANDA) to market an extended release methylphenidate hydrochloride product, for which Concerta® is the reference listed drug product. The ANDA is currently under review with FDA.

The settlement includes a patent license and covenant, under existing ALZA Corporation patents under which Kremers Urban may commercially launch its methylphenidate ANDA product on July 1, 2012, or earlier under certain circumstances, pending FDA approval.

About Kremers Urban

Kremers Urban is the generic subsidiary of UCB. It is a specialty generic pharmaceutical company focused on difficult, "high barrier" to entry generic products. To learn more visit www.kremersurban.com.

For More Information Contact:
Antje Witte, Investor Relations
+49 2173 48 1866
[email protected]

SOURCE Kremers Urban Pharmaceuticals Inc.

Suggested Articles

Colorado is making a play for a Japanese CDMO in hopes it will invest about $100 million in an empty AstraZeneca plant in Boulder.

Esperion's Nexletol has had a rough road to approval after safety concerns nearly derailed its quest. But an FDA nod has the drug ready for market.

The FDA approved Lundbeck's Vyepti, formerly known as eptinezumab, as the first IV therapy to prevent migraines in adults.